Ashish Kacholia is a renowned Indian investor known for his strategic investments in mid-cap stocks and small-cap stocks. Often referred to as the “Big Whale” of Dalal Street, he co-founded
Hungama Digital has built a strong reputation for identifying multibagger stocks early. His Portfolio choices are closely tracked by retail and institutional investors alike. As per the latest corporate shareholdings filed, Ashish Kacholia publicly holds 48 stocks with a net worth of over Rs. 2,793.5 crore.
Here are the Ashish Kacholia stocks with 5-year Net profit CAGR up to 85%;
1. Fineotex Chemical Ltd
Fineotex Chemical Limited is an India-based company that is engaged in the business of manufacturing textile chemicals, auxiliaries, and specialty chemicals. Its product categories include textile chemicals, oil and gas, and cleaning and hygiene. With a market capitalization of Rs 3,032 crore, the shares closed at Rs 265 per share, decreased around 0.79 percent as compared to the previous closing price.
The company’s consolidated net profit rose from Rs 14 crores in FY20 to Rs 109 crores in FY25, marking a notable turnaround. With a net profit CAGR of 50.75 percent over five years, this reflects effective growth strategies and sustained profitability across its various business segments.
2. Zaggle Prepaid Ocean Services Ltd
Zaggle Prepaid provides a range of fintech services and products. They have a wide touchpoint network and SaaS products like payroll and tax software in their portfolio. The company provides services to a broad spectrum of corporate clients in sectors like banking, finance, technology, healthcare, and many more. With a market capitalization of Rs 5,857 crore, the shares closed at Rs 436 per share, decreased around 0.77 percent as compared to the previous closing price.
The company’s consolidated net profit rose from Rs 4 crores in FY20 to Rs 87 crores in FY25, marking a notable turnaround. With a net profit CAGR of 85.14 percent over five years, this reflects effective growth strategies and sustained profitability across its various business segments.
3. Beta Drugs Ltd
Beta Drugs Limited manufactures oncology drugs. The company offers a variety of oncolog medicines such as pills, capsules, and injections. The company’s portfolio includes over 50 medications that address a variety of cancer disorders, such as breast, brain, bone, and others. With a market capitalization of Rs 1,827 crore, the shares closed at Rs 1,810 per share, increased around 0.93 percent as compared to the previous closing price.
The company’s consolidated net profit rose from Rs 9 crores in FY20 to Rs 42 crores in FY25, marking a notable turnaround. With a net profit CAGR of 36.08 percent over five years, this reflects effective growth strategies and sustained profitability across its various business segments.
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
